Literature DB >> 20182344

Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.

Edward B Stelow1, Ruthy Shaco-Levy, Fei Bao, Joaquin Garcia, David S Klimstra.   

Abstract

BACKGROUND: Pancreatic acinar cell carcinomas (ACCs) are clinically and pathologically distinct from pancreatic ductal adenocarcinomas (PDAs). Whereas endocrine differentiation has been well shown in ACCs, significant ductal components are rare. This paper reviews the clinicopathologic features of a series of ACCs with prominent ductal differentiation.
DESIGN: Cases of pancreatic ACCs with significant ductal differentiation were identified in the surgical pathology databases of 2 academic centers. Patient clinical information, gross and histologic features, and histochemical and immunohistochemical (IHC) results were recorded. Cases were tested for KRAS2 mutations.
RESULTS: Eleven cases were identified (10 men and 1 woman; age range 52 to 79 y). Four patients presented with jaundice. At last follow-up, 7 patients died of disease and 2 others had recurrences. Tumors measured between 2 and 5.5 cm and were ill-defined, nodular, and multilobulated. Ten were located in the head of the pancreas. All but 2 exhibited extrapancreatic invasion. All cases showed significant evidence of both acinar and ductal differentiation, estimated to be at least 25% of the neoplastic cells, and 3 cases in addition had endocrine differentiation in more than 25% of cells. Five cases were predominately acinar with intracellular and sometimes extracellular mucin ("mucinous acinar cell carcinoma" pattern). Six cases seemed more mixed with areas recapitulating typical PDAs whereas the other portions of the tumors seemed akin to typical acinar cell carcinomas ("combined acinar and ductal" pattern). IHC positive staining results were as: trypsin (92%), chymotrypsin (92%), monoclonal carcinoembryonic antigen (100%), CK19 (100%), B72.3 (73%), CA19.9 (73%), CD56 (18%), synaptophysin (36%), and chromogranin (36%). One case showed p53 over-expression aznd none showed DPC4/Smad4 loss. Two cases had KRAS2 mutations.
CONCLUSION: Despite the early embryologic divergence of acinar and ductal cell lineages, rare pancreatic tumors have both acinar and ductal differentiation, usually predominantly the former. The clinical course is highly aggressive.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182344     DOI: 10.1097/PAS.0b013e3181cfcac7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  25 in total

1.  Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases.

Authors:  Olca Basturk; Laura Tang; Ralph H Hruban; Volkan Adsay; Zhaohai Yang; Alyssa M Krasinskas; Efsevia Vakiani; Stefano La Rosa; Kee-Taek Jang; Wendy L Frankel; Xiuli Liu; Lizhi Zhang; Thomas J Giordano; Andrew M Bellizzi; Jey-Hsin Chen; Chanjuan Shi; Peter Allen; Diane L Reidy; Christopher L Wolfgang; Burcu Saka; Neda Rezaee; Vikram Deshpande; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2014-04       Impact factor: 6.394

Review 2.  Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.

Authors:  Chakshu Sharma; Karim M Eltawil; Paul D Renfrew; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

3.  Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy.

Authors:  Maeve A Lowery; David S Klimstra; Jinru Shia; Kenneth H Yu; Peter J Allen; Murray F Brennan; Eileen M O'Reilly
Journal:  Oncologist       Date:  2011-10-31

4.  Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases.

Authors:  Frank Bergmann; Sebastian Aulmann; Bence Sipos; Matthias Kloor; Anja von Heydebreck; Johannes Schweipert; Andreas Harjung; Philipp Mayer; Werner Hartwig; Gerhard Moldenhauer; David Capper; Gerhard Dyckhoff; Kolja Freier; Esther Herpel; Anja Schleider; Peter Schirmacher; Gunhild Mechtersheimer; Günter Klöppel; Hendrik Bläker
Journal:  Virchows Arch       Date:  2014-10-09       Impact factor: 4.064

5.  Pathology and genetics of pancreatic neoplasms with acinar differentiation.

Authors:  Laura D Wood; David S Klimstra
Journal:  Semin Diagn Pathol       Date:  2014-10-02       Impact factor: 3.464

6.  Pancreatic ductal and acinar cell neoplasms in Carney complex: a possible new association.

Authors:  Sébastien Gaujoux; Frédérique Tissier; Bruno Ragazzon; Vinciane Rebours; Emmanouil Saloustros; Karine Perlemoine; Caroline Vincent-Dejean; Guillaume Meurette; Elisabeth Cassagnau; Bertrand Dousset; Xavier Bertagna; Anelia Horvath; Benoit Terris; J Aidan Carney; Constantine A Stratakis; Jérôme Bertherat
Journal:  J Clin Endocrinol Metab       Date:  2011-09-07       Impact factor: 5.958

7.  Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas.

Authors:  Micaela Poetsch; Martin Hemmerich; Christoph Kakies; Britta Kleist; Eduard Wolf; Frank vom Dorp; Oliver W Hakenberg; Chris Protzel
Journal:  Virchows Arch       Date:  2010-11-18       Impact factor: 4.064

8.  Natural History and Treatment Trends in Pancreatic Cancer Subtypes.

Authors:  Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

9.  Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.

Authors:  Michelle D Reid; Christina R Stallworth; Melinda M Lewis; Gizem Akkas; Bahar Memis; Olca Basturk; Volkan Adsay
Journal:  Cancer Cytopathol       Date:  2015-09-28       Impact factor: 5.284

10.  Mixed acinar-neuroendocrine-ductal carcinoma of the pancreas: a tale of three lineages.

Authors:  Mark J Anderson; Christina A Kwong; Mohammed Atieh; Sam G Pappas
Journal:  BMJ Case Rep       Date:  2016-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.